Celldex Stock (CLDX:NSD) Analysis:
Last Closing Price: $38.81
Consensus Analyst Rating: Strong Buy
12-Month Price Target: $66.67
Market CAP: $1.75 Billion
Guggenheim lowered their Celldex stock (CLDX:NSD) price target from $68.00 to $63.00 and assigned the stock a “Buy” rating in a report published on Friday, November 11th.
1 analyst has assigned a “Sell” rating to the Celldex stock, while 4 have assigned a “Buy” rating. Celldex Therapeutics stock has an average rating of “Moderate Buy” and an average price target of $66.67.
Celldex Stock Price Rises 4.6%
On Thursday, CLDX stock price increased by $1.71, reaching $38.81. Compared to its average volume of 607,713, 524,695 shares of the stock changed hands.
The company has a $1.83 billion market capitalization, a P/E ratio of -17.17, and a beta of 2.32. The company’s 50-day and 200-day moving averages are $33.49 and $30.45, respectively.
The 52-week low for Celldex Therapeutics is $19.85 and the 52-week high is $42.46.
Celldex Stock-Institutional Buying & Selling:
Several institutional investors and hedge funds have purchased and sold shares of Celldex stock in recent months.
During the first quarter, Wellington Management Group LLP increased its position in Celldex Therapeutics by 61.5%. After acquiring an additional 1,343,864 shares during the preceding quarter, Wellington Management Group LLP now holds 3,529,840 shares of the biopharmaceutical company’s stock valued at $120,227,000.
State Street Corporation increased its Celldex Therapeutics holdings by 20.4% in the second quarter. State Street Corp now holds 3,228,852 shares of the biopharmaceutical company’s stock, valued at $87,050,000, after purchasing an additional 546,124 shares in the last recent quarter.
During the third quarter, Vanguard Group Inc. increased its holdings in Celldex Therapeutics by 1.6%. In the most recent quarter, Vanguard Group Inc. acquired an additional 40,009 shares of the biopharmaceutical company’s stock, increasing its holdings to 2,475,381 shares worth $69,583,000.
RA Capital Management L.P. increased its Celldex Therapeutics holdings by 15% in the first quarter. RA Capital Management L.P. After purchasing an additional 270,205 shares during the period, the investor now owns 2,075,000 shares of the biopharmaceutical company’s stock worth $70,675,000.
In the first quarter, Viking Global Investors LP increased its holdings in Celldex Therapeutics by 143.7%. After acquiring an additional 1,088,775 shares during the period, Viking Global Investors LP now holds 1,846,647 shares of the biopharmaceutical company’s stock worth $62,897,000.
About Celldex Therapeutics Inc. (CLDX:NSD):
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.
The company’s clinical development programs CDX-0159, CDX-1140, a key activator of the immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
The company has research collaboration and license agreements with the University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.